Abstract
Purpose
ASP9853 is an inhibitor of inducible nitric oxide (NO) synthase (iNOS) dimerization, which results in decreased NO production. Here, we report preclinical pharmacology of ASP9853 and the impact of ASP9853 in combination with a taxane on tumor volume in vivo. In addition, a Phase I open-label study of ASP9853 plus docetaxel was conducted to assess this combination in patients with advanced solid tumors.
Methods
The preclinical efficacy of ASP9853 in combination with a taxane was studied in tumor-bearing mice. In the clinic, patients with solid tumors that had progressed or failed to respond to previous therapies were treated with once–daily ASP9853 in combination with docetaxel once every 3 weeks to assess safety and tolerability and to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D) of the combination.
Results
ASP9853 in combination with docetaxel showed greater tumor growth inhibition than docetaxel alone against non-small lung cancer xenografts. Twenty patients were treated with ASP9853 and docetaxel. Five patients experienced neutropenic dose-limiting toxicities. Owing to overall toxicity that limited further dose escalation, the ASP9853 concentrations predicted for efficacy, based on the preclinical data, were not achieved. Due to toxicity and lack of clear efficacy, the study was terminated without determination of MTD or RP2D.
Conclusions
Inhibition of iNOS by ASP9853 in combination with docetaxel was not tolerable and resulted in the possible potentiation of neutropenia. Manipulation of the iNOS pathway, with or without chemotherapy, appears to be more complicated than initially expected.
Similar content being viewed by others
References
Sessa WC (2009) Molecular control of blood flow and angiogenesis: role of nitric oxide. J Thromb Haemost 7(Suppl 1):35–37
Rosselli M, Keller PJ, Dubey RK (1998) Role of nitric oxide in the biology, physiology and pathophysiology of reproduction. Hum Reprod Update 4:3–24
Wink DA, Hines HB, Cheng RY, Switzer CH, Flores-Santana W, Vitek MP, Ridnour LA, Colton CA (2011) Nitric oxide and redox mechanisms in the immune response. J Leukoc Biol 89:873–891
Thomas DD, Miranda KM, Colton CA, Citrin D, Espey MG, Wink DA (2003) Heme proteins and nitric oxide (NO): the neglected, eloquent chemistry in no redox signaling and regulation. Antioxid Redox Signal 5:307–317
Landar A, Darley-Usmar VM (2003) Nitric oxide and cell signaling: modulation of redox tone and protein modification. Amino Acids 25:313–321
Gow AJ, Farkouh CR, Munson DA, Posencheg MA, Ischiropoulos H (2004) Biological significance of nitric oxide-mediated protein modifications. Am J Physiol Lung Cell Mol Physiol 287:L262–L268
Andrew PJ, Mayer B (1999) Enzymatic function of nitric oxide synthases. Cardiovasc Res 43:521–531
Predonzani A, Cali B, Agnellini AH, Molon B (2015) Spotlights on immunological effects of reactive nitrogen species: when inflammation says nitric oxide. World J Exp Med 5:64–76
Janakiram NB, Rao CV (2012) Inos-selective inhibitors for cancer prevention: promise and progress. Future Med Chem 4:2193–2204
Zamora R, Vodovotz Y, Billiar TR (2000) Inducible nitric oxide synthase and inflammatory diseases. Mol Med 6:347–373
Lechner M, Lirk P, Rieder J (2005) Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin. Semin Cancer Biol 15:277–289
Hibbs J, Taintor R, Vavrin Z, Granger D, Drapier J-C, Amber I, Lancaster J (1990) Synthesis of nitric oxide from a terminal guanidino nitrogen atom of l-arginine: a molecular mechanism regulating cellular proliferation that targets in intracellular iron. In: Moncada S, Higgs E (eds) Nitric oxide from l-arginine: a bioregulatory system. Elsevier, Amsterdam, pp 189–223
Albina JE, Reichner JS (1998) Role of nitric oxide in mediation of macrophage cytotoxicity and apoptosis. Cancer Metastasis Rev 17:39–53
Jenkins DC, Charles IG, Thomsen LL, Moss DW, Holmes LS, Baylis SA, Rhodes P, Westmore K, Emson PC, Moncada S (1995) Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA 92:4392–4396
Klotz T, Bloch W, Volberg C, Engelmann U, Addicks K (1998) Selective expression of inducible nitric oxide synthase in human prostate carcinoma. Cancer 82:1897–1903
Takahashi M, Fukuda K, Ohata T, Sugimura T, Wakabayashi K (1997) Increased expression of inducible and endothelial constitutive nitric oxide synthases in rat colon tumors induced by azoxymethane. Cancer Res 57:1233–1237
Grimm EA, Sikora AG, Ekmekcioglu S (2013) Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target. Clin Cancer Res 19:5557–5563
Chanvorachote P, Nimmannit U, Stehlik C, Wang L, Jiang BH, Ongpipatanakul B, Rojanasakul Y (2006) Nitric oxide regulates cell sensitivity to cisplatin-induced apoptosis through s-nitrosylation and inhibition of bcl-2 ubiquitination. Cancer Res 66:6353–6360
Engels K, Knauer SK, Loibl S, Fetz V, Harter P, Schweitzer A, Fisseler-Eckhoff A, Kommoss F, Hanker L, Nekljudova V, Hermanns I, Kleinert H, Mann W, du Bois A, Stauber RH (2008) NO signaling confers cytoprotectivity through the survivin network in ovarian carcinomas. Cancer Res 68:5159–5166
Fetz V, Bier C, Habtemichael N, Schuon R, Schweitzer A, Kunkel M, Engels K, Kovacs AF, Schneider S, Mann W, Stauber RH, Knauer SK (2009) Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin. Int J Cancer 124:2033–2041
Sikora AG, Gelbard A, Davies MA, Sano D, Ekmekcioglu S, Kwon J, Hailemichael Y, Jayaraman P, Myers JN, Grimm EA, Overwijk WW (2010) Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res 16:1834–1844
Zhang HX, Deng C, Liu OS, Liu XL, Wu F, Wang JJ, Feng YQ, Hu CH, Tang ZG (2014) Inducible nitric oxide inhibitor enhances the anti-tumor effect of cisplatin on CNE-2 cells by inducing cell apoptosis. Eur Rev Med Pharmacol Sci 18:2789–2797
Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the tax 327 study. J Clin Oncol 26:242–245
Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095–2103
Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group. J Clin Oncol 18:2354–2362
Chida N, Hirasawa Y, Ohkawa T, Ishii Y, Sudo Y, Tamura K, Mutoh S (2005) Pharmacological profile of FR260330, a novel orally active inducible nitric oxide synthase inhibitor. Eur J Pharmacol 509:71–76
Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D (1999) Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284:808–812
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised recist guideline (version 1.1). Eur J Cancer 45:228–247
Kenmotsu H, Tanigawara Y (2015) Pharmacokinetics, dynamics and toxicity of docetaxel: why the japanese dose differs from the western dose. Cancer Sci 106:497–504
Mitchell PL, Basser R, Chipman M, Grigg A, Cebon J, Davis ID, Zalcberg J, Ng S, Appia F, Green M (2003) A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumours. Ann Oncol 14:788–794
Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162–174
Mazzoni A, Bronte V, Visintin A, Spitzer JH, Apolloni E, Serafini P, Zanovello P, Segal DM (2002) Myeloid suppressor lines inhibit t cell responses by an no-dependent mechanism. J Immunol 168:689–695
Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, Dolcetti L, Bronte V, Borrello I (2006) Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 203:2691–2702
Jayaraman P, Parikh F, Lopez-Rivera E, Hailemichael Y, Clark A, Ma G, Cannan D, Ramacher M, Kato M, Overwijk WW, Chen SH, Umansky VY, Sikora AG (2012) Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release. J Immunol 188:5365–5376
Acknowledgments
We would like to thank Michelle Utton-Mishra, Choice Healthcare Solutions, for medical writing assistance, funded by Astellas Pharma Inc.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
J.L. has no COIs; P.L.R. has received consultancy/advisory fees from Astellas, Pfizer, Genetech and Astex; G.I.S. reports funding to the Dana-Farber Cancer Institute Early Drug Development Center for conduct of the study; J.I. has not COIs; A.K., R.S., T.Y., A.F. and C.D. are employees of Astellas Pharma Global Development, Inc.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Luke, J.J., LoRusso, P., Shapiro, G.I. et al. ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumors. Cancer Chemother Pharmacol 77, 549–558 (2016). https://doi.org/10.1007/s00280-016-2967-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-016-2967-0